New Technologies in Therapeutic Antibody Development: The Next Frontier for Treating Infectious Diseases
SM Keating, BW Higgins - Antiviral Research, 2024 - Elsevier
Adaptive immunity to viral infections requires time to neutralize and clear viruses to resolve
infection. Fast growing and pathogenic viruses are quickly established, are highly …
infection. Fast growing and pathogenic viruses are quickly established, are highly …
[HTML][HTML] Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
Although young children generally experience mild symptoms following infection with SARS-
CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines …
CoV-2, severe acute and long-term complications can occur. SARS-CoV-2 mRNA vaccines …
[HTML][HTML] The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies
Streptococcus pyogenes can cause invasive disease with high mortality despite adequate
antibiotic treatments. To address this unmet need, we have previously generated an opsonic …
antibiotic treatments. To address this unmet need, we have previously generated an opsonic …
[HTML][HTML] Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection
K Mader, LB Dustin - Antibodies, 2024 - mdpi.com
The vast majority of antibodies generated against a virus will be non-neutralising. However,
this does not denote an absence of protective capacity. Yet, within the field, there is typically …
this does not denote an absence of protective capacity. Yet, within the field, there is typically …
[HTML][HTML] Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity …
Vaccination with the primary two-dose series of SARS-CoV-2 mRNA protects against
infection with the ancestral strain, and limits the presentation of severe disease after re …
infection with the ancestral strain, and limits the presentation of severe disease after re …
Protective Non-neutralizing anti–N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA. 2.86-JN. 1 with Superfluous In Vivo …
A Izadi, M Godzwon, A Söderlund Strand… - The Journal of …, 2024 - journals.aai.org
Substantial evidence supports that Fc-mediated effector functions of anti-spike Abs
contribute to anti–SARS-Cov-2 protection. We have previously shown that two non …
contribute to anti–SARS-Cov-2 protection. We have previously shown that two non …
Consideration of C1q and FcRn binding to allotypically disparate IgG3 could aid in engineering more efficacious anti-SARS-CoV-2 mAbs
JP Pandey - Proceedings of the National Academy of …, 2023 - National Acad Sciences
Izadi et al.(1) have added to the increasing body of evidence that IgG3 monoclonal
antibodies (mAbs) are more potent than their IgG1 counterparts in mediating Fc-mediated …
antibodies (mAbs) are more potent than their IgG1 counterparts in mediating Fc-mediated …
Local Immune Activation and Age Impact on Humoral Immunity in Mice, with a Focus on IgG Sialylation
Age alters the host's susceptibility to immune induction. Humoral immunity with circulating
antibodies, particularly immunoglobulin G (IgG), plays an essential role in immune …
antibodies, particularly immunoglobulin G (IgG), plays an essential role in immune …
Protective non-neutralizing mAbs Ab94 and Ab81 retain high-affinity and potent Fc-mediated function against SARS-CoV-2 variants from Omicron to XBB1. 5
A Izadi, M Godzwon, M Ohlin, P Nordenfelt - bioRxiv, 2023 - biorxiv.org
Antibodies play a central role in the immune defense against SARS-CoV-2. There is
substantial evidence supporting that Fc-mediated effector functions of anti-spike antibodies …
substantial evidence supporting that Fc-mediated effector functions of anti-spike antibodies …
Reply to Pandey: IgG3 allotypes, modulation of antigen binding by constant domain changes, and therapeutic applications of Fc engineering
It was with great interest that we read the comments made by Pandey (1) on our recent study
(2), showing that subclassswitched IgG3 mAbs display more potent complement activation …
(2), showing that subclassswitched IgG3 mAbs display more potent complement activation …